Patents by Inventor Eric Eugene Boros

Eric Eugene Boros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
    Patent number: 8691991
    Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: April 8, 2014
    Assignees: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian Alvin Johns, Eric Eugene Boros, Takshi Kawasuji, Cecilia S. Koble, Noriyuki Kurose, Hitoshi Murai, Ronald George Sherrill, Jason Gordon Weatherhead
  • Chemical compounds
    Patent number: 8222261
    Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Subba R Katamreddy, Richard Dama Caldwell, Dennis Heyer, Vincente Samano, James Benjamin Thompson, Andrew J Carpenter, Christopher R Conlee, Eric Eugene Boros, Brian D Thompson
  • GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF
    Publication number: 20100305207
    Abstract: This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition containing the compound and to processes for preparing the compound and pharmaceutical composition.
    Type: Application
    Filed: September 25, 2008
    Publication date: December 2, 2010
    Inventors: Pierette Banker, Eric Eugene Boros, Scott Howard Dickerson, Istvan Kaldor, Cecilia S. Koble, Michael Tolar Martin, Steven Meagher Sparks, Stephen Andrew Thomson
  • CCR5 antagonists as therapeutic agents
    Patent number: 7645771
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 12, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
  • Condensed heterocyclic compounds as calcitonin agonists
    Patent number: 7189851
    Abstract: The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: March 13, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Ashok Bhandari, Eric Eugene Boros, David John Cowan, Anthony Louis Handlon, Clifton Earl Hyman, Jeffrey Alan Oplinger, Michael Howard Rabinowitz, Philip Stewart Turnbull
  • Substituted isoquinolines as ultra short acting neuromuscular blockers
    Patent number: 6187789
    Abstract: Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is a halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z1 and Z2 are methyl; W1 and W2 are carbon; and A is a pharmaceutically acceptable anion.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: February 13, 2001
    Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.
    Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano
  • Substituted isoquinolines as ultra short acting neuromuscular blockers
    Patent number: 6177445
    Abstract: Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independently from 0 to 4; X1 and X2 are independently halogen; ha and hb are independenity from 0 to 2; Z1 and Z2 are indepentdently hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl with the proviso that Z1 and Z2 are not both hydrogen; Y1, Y2, and Y3 and Y4 are independently hydrogen, halogen or C1-3 alkoxy; m and p are independently 1 to 6; n and r are independently 0 to 4; with the proviso the if ha and hb are both 0, then r is 0 and n is 0 to 2; R1 to R14 are independently hydrogen, halogen, C1-3 alkoxy, or R2 and R3 together with the carbon atoms to which they are bonded, R5 and R6 together with the carbon atoms to which they are bonded, R9 and R10 together with the carbon atoms to which they are bonded, R12 and R13 together with the carbon atoms to which they are bonded, may
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: January 23, 2001
    Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.
    Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano